Introduction to Erleva

Erleva is a targeted cancer therapy medication primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It belongs to a class of drugs known as epidermal growth factor receptor (EGFR) inhibitors. By specifically targeting and inhibiting the activity of the EGFR, Erleva helps to slow down or stop the growth of cancer cells. This precision in targeting cancer cells makes Erleva an essential part of cancer treatment regimens, providing hope and improved outcomes for patients battling these challenging conditions.

Composition of Erleva

The active ingredient in Erleva is Erlotinib, which is present in a dosage of 100mg per tablet. Erlotinib works by blocking the action of EGFR, a protein found on the surface of many cancer cells. EGFR is involved in the signaling pathways that regulate cell division and survival. By inhibiting EGFR, Erlotinib effectively disrupts these pathways, leading to reduced cancer cell proliferation and increased apoptosis (programmed cell death). This targeted action is crucial for the medication's effectiveness in managing and treating certain types of cancer.

Uses for Erleva

Erleva is primarily used for the following purposes:

• Treatment of non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations.
• Management of locally advanced, unresectable, or metastatic pancreatic cancer in combination with other chemotherapy agents.
• Potential off-label uses as determined by a healthcare provider based on individual patient needs.

Side Effects of Erleva

Common side effects associated with Erleva include:

• Rash and skin reactions
• Diarrhea
• Loss of appetite
• Nausea and vomiting
• Fatigue
• Difficulty breathing
• Cough
• Increased risk of infection

Precautions for Erleva

Patients taking Erleva should consider the following precautions:

• Inform your healthcare provider about any allergies or pre-existing conditions.
• Avoid exposure to sunlight or UV rays, as Erleva can increase skin sensitivity.
• Regularly monitor liver and kidney function through blood tests as advised by your doctor.
• Inform your doctor about all other medications you are taking to avoid potential interactions.
• Use effective contraception to prevent pregnancy during treatment, as Erleva can harm an unborn baby.

Specifications of Erleva

Erleva is available in the form of oral tablets containing 100mg of Erlotinib. Currently, there are no formulations of Erleva available as injections, syrups, or capsules. It is important to follow the prescribed dosage and administration guidelines provided by your healthcare provider to ensure optimal effectiveness and safety.

Conclusion

Erleva, with its active ingredient Erlotinib, plays a vital role in the treatment of certain types of cancer, particularly non-small cell lung cancer and pancreatic cancer. Its targeted approach to inhibiting EGFR makes it a powerful tool in oncology. Patients must adhere to their healthcare provider's guidance and report any side effects or concerns promptly. With appropriate use, Erleva can significantly contribute to improved cancer treatment outcomes and enhance the quality of life for patients.